NEW YORK (GenomeWeb) – Cancer drug developer Celsion last week announced that it had closed its acquisition of nucleic acid drug developer Egen, giving it a portfolio of clinical and preclinical drug candidates, as well as a lung-specific delivery technology for RNAi and microRNA therapeutics.

Under the deal, a wholly owned subsidiary of Celsion acquired the assets of Egen in exchange for $10.6 million in stock and $3.4 million in cash.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.

In Science this week: factors influencing retrotransposon integration sites, and more.

A bioethicist argues for the responsible use of germline gene editing.

Some breweries are using DNA-based testing to determine whether unwanted bacteria are affecting their beers, The Verge reports.

Standardized N-of-1 trials will be needed to test out personalized medicines, writes Nicholas Schork from the J. Craig Venter Institute at Nature.